|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
Seminar by Professor Jane Armitage FRCP FFPH , Professor of Clinical Trials and Epidemiology, Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford
Wednesday 25th January at 1pm, Seminar Rooms, Strangeways Research Laboratory.
Low-density lipoprotein [LDL] cholesterol has been recognised as a causal risk factor for coronary heart disease for many decades based on data from observational studies and randomised intervention trials. The observational associations between LDL cholesterol and risk are less clear for cerebrovascular disease, but the intervention trials clearly show reductions in risk of ischaemic stroke with LDL lowering interventions. As a result of a large body of high-quality randomised trial data showing both efficacy and safety, statins have become the first-line drug for LDL -lowering. They are now largely off-patent and widely used for both secondary and primary prevention of cardiovascular disease. New potent LDL -lowering treatments use monoclonal antibodies to block the activity of PCSK9 and have recently been licensed for use in limited circumstances. Results from the first of the large outcome trials of these treatments are imminent. The drive to find a market for these and other lipid-modifying drugs in development may be behind the recent increase in interest and publications on ‘statin intolerance’. Claims have been made that intolerance to statin therapy is a common problem, but the data from large blinded randomised trials do not support this. Widespread media coverage of this controversy has resulted in people who might gain substantial benefit choosing to discontinue statin treatment. Other new lipid modifying agents are in development including oral CETP -inhibitors, and oligonucleotides and small interfering RNAs which can block specific lipid pathways.
If you have a question about this list, please contact: bk230. If you have a question about a specific talk, click on that talk to find its organiser.
0 upcoming talks and 0 talks in the archive.
Please see above for contact details for this list.
Other listsBritish Antarctic Survey's Natural Complexity: Data and Theory in Dialogue APDE Dimer observables and Cauchy-Riemann operators
Other talksLies, Damn'd lies and statistics: why it is (almost) impossible to communicate risk ethically The Power Switch; How Power is Changing in a Networked World - an international symposium Defining the (Patho-) Physiology of Receptors for a short-chain fatty acids Dr Becca Asquith: KIRs, CD8 T cell dynamics and control of chronic viral infection The Emergence of the Sovereign Consumer – from Adam Smith to the Socialist Calculation Debate Reality discrimination deficits in hallucinations